Related references
Note: Only part of the references are listed.Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease (COPD): Boon or Bane?
Alan G. Kaplan
JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE (2020)
An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naive Patients With COPD
Dave Singh et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2019)
The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD
Antonio Anzueto et al.
AMERICAN JOURNAL OF MEDICINE (2018)
Effect of Bronchodilation, Exercise Training, and Behavior Modification on Symptoms and Physical Activity in Chronic Obstructive Pulmonary Disease
Thierry Troosters et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
Masakazu Ichinose et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2018)
Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial
Jens M. Hohlfeld et al.
LANCET RESPIRATORY MEDICINE (2018)
Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial
Peter M. A. Calverley et al.
LANCET RESPIRATORY MEDICINE (2018)
Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials
Gary T. Ferguson et al.
RESPIRATORY MEDICINE (2018)
Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
Mohamed Ismail Abdul Aziz et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2018)
Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease
Francois Maltais et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2018)
Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease
Mark T. Dransfield et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD
Denis E. O'Donnell et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Long acting muscarinic antagonists vs. long-acting β2 agonists in COPD exacerbations: a systematic review and meta analysis
Israel Silva Maia et al.
JORNAL BRASILEIRO DE PNEUMOLOGIA (2017)
Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies
Gary T. Ferguson et al.
NPJ PRIMARY CARE RESPIRATORY MEDICINE (2017)
A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease
Marc Miravitlles et al.
RESPIRATORY RESEARCH (2017)
Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis
Marc Miravitlles et al.
RESPIRATORY RESEARCH (2017)
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
Claus F. Vogelmeier et al.
RESPIRATORY RESEARCH (2017)
Effect of tiotropium on COPD exacerbations: A systematic review
David M. G. Halpin et al.
RESPIRATORY MEDICINE (2016)
Striving for optimal bronchodilation: focus on olodaterol
Cristoforo Incorvaia et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2016)
The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via A Accuhaler® (ENERGITO® study)
Kai-Michael Beeh et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2016)
Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial
Henrik Watz et al.
LANCET RESPIRATORY MEDICINE (2016)
Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD
Andre-Bernard Tonnel
International Journal of Chronic Obstructive Pulmonary Disease (2016)
Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies
Francois Maltais et al.
RESPIRATORY RESEARCH (2016)
Total and State-Specific Medical and Absenteeism Costs of COPD Among Adults Aged ≥ 18 Years in the United States for 2010 and Projections Through 2020
Earl S. Ford et al.
CHEST (2015)
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)
Roland Buhl et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D
Huib A. M. Kerstjens et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2015)
Antibiotic prophylaxis in COPD: Why, when, and for whom?
Marc Miravitlles et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2015)
The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease
Kai-Michael Beeh et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2015)
Indacaterol vs tiotropium in COPD patients classified as GOLD A and B
Donald A. Mahler et al.
RESPIRATORY MEDICINE (2015)
A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease
M. Reza Maleki-Yazdi et al.
RESPIRATORY MEDICINE (2015)
Tiotropium plus olodaterol shows clinically meaningful improvements in quality of life
Dave Singh et al.
RESPIRATORY MEDICINE (2015)
One-year change in health status and subsequent outcomes in COPD
Sarah Wilke et al.
THORAX (2015)
Immune Dysfunction in Patients with Chronic Obstructive Pulmonary Disease
Tariq A. Bhat et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2015)
Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies
Andrea Koch et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2014)
Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studies
Richard ZuWallack et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2014)
Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
Neil S. Roskell et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2014)
Efficacy and safety of olodaterol once daily delivered via Respimat (R) in patients with GOLD 2-4 COPD: results from two replicate 48-week studies
Gary T. Ferguson et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2014)
Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD
David Price et al.
PRIMARY CARE RESPIRATORY JOURNAL (2013)
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study
Marc L. Decramer et al.
LANCET RESPIRATORY MEDICINE (2013)
Comparison of Indacaterol With Tiotropium or Twice-Daily Long-Acting β-Agonists for Stable COPD
Gustavo J. Rodrigo et al.
CHEST (2012)
Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality
Samy Suissa et al.
THORAX (2012)
Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population
Margaret K. Pasquale et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2012)
Lung function decline in COPD
Claudio Tantucci et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2012)
Functional and Biochemical Rationales for the 24-Hour-Long Duration of Action of Olodaterol
Paola Casarosa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Claus Vogelmeier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
24-hour Bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD
J. A. van Noord et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2011)
Impact of changes in physical activity on health-related quality of life among patients with COPD
C. Esteban et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients
E. D. Bateman et al.
RESPIRATORY MEDICINE (2010)
The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD
Mario Cazzola et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2010)
Treatment of COPD: the sooner the better?
Marc Decramer et al.
THORAX (2010)
Inhaled muscarinic antagonists for COPD-does an anti-inflammatory mechanism really play a role?
Michael Trevethick et al.
CURRENT OPINION IN PHARMACOLOGY (2009)
Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial
Marc Decramer et al.
LANCET (2009)
Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations
David Halpin et al.
Primary Care Respiratory Journal (2009)
A 4-year trial of tiotropium in chronic obstructive pulmonary disease
Donald P. Tashkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The cost of moderate and severe COPD exacerbations to the Canadian healthcare system
N. Mittmann et al.
RESPIRATORY MEDICINE (2008)
Exacerbations and lung function decline in COPD: New insights in current and ex-smokers
D. Makris et al.
RESPIRATORY MEDICINE (2007)
Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease -: A population-based cohort study
Judith Garcia-Aymerich et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
Peter M. A. Calverley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Tiotropium, a novel muscarinic M3 receptor antagonist, improved symptoms of chronic obstructive pulmonary disease complicated by chronic heart failure
Mahoto Kato et al.
CIRCULATION JOURNAL (2006)
The effect of tiotropium on exacerbations and airflow in patients with COPD
D Dusser et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD
V Brusasco et al.
THORAX (2003)
Risk factors of readmission to hospital for a COPD exacerbation:: a prospective study
J Garcia-Aymerich et al.
THORAX (2003)
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
R Casaburi et al.
EUROPEAN RESPIRATORY JOURNAL (2002)
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial
PS Burge et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
